NCT01819168

Brief Summary

The aim of this retrospective study is to analyze if nighttime antimuscarincs may be more effective in treating patients with nocturia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
38

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Mar 2013

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2013

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

March 21, 2013

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 27, 2013

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2015

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2016

Completed
Last Updated

September 7, 2016

Status Verified

February 1, 2016

Enrollment Period

2 years

First QC Date

March 21, 2013

Last Update Submit

September 4, 2016

Conditions

Overactive Bladder Syndrome

Outcome Measures

Primary Outcomes (1)

  • bladder diary

    To clarity any difference of reduction in the episodes of nocturia between these two groups.

    3 months

Secondary Outcomes (1)

  • Frequency and Urgency

    3 months

Eligibility Criteria

Age20 Years - 99 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

We will perform a retrospective study to review the data of bladder diary, urodynamic studies and clinical data of patients who underwent tolterodine SR treatment once per day for 12 weeks in Department of Obstetrics \& Gynecology in National Taiwan University Hospital and Far Eastern Memorial Hospital.

You may qualify if:

  • patients who underwent tolterodine SR treatment once per day for 12 weeks in Department of Obstetrics \& Gynecology in National Taiwan University Hospital and Far Eastern Memorial Hospital

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Far Eastern Memorial Hospital

Banqiao District, New Taipei, 22050, Taiwan

Location

Study Design

Study Type
observational
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief, Department of Obstetrics & Gynecology

Study Record Dates

First Submitted

March 21, 2013

First Posted

March 27, 2013

Study Start

March 1, 2013

Primary Completion

March 1, 2015

Study Completion

April 1, 2016

Last Updated

September 7, 2016

Record last verified: 2016-02

Locations

TW(1)